Results for
"[search-keyword]"
Sponsor content
18 result(s) found, displaying 1 to 10
- VafseoPrescription medicine decision summaryVafseo (vadadustat) is approved to treat anaemia associated with chronic kidney disease in adults on chronic maintenance dialysis.
- VAFSEO vadadustat 150 mg tablet blister pack (384156)ARTGAustralian Register of Therapeutic Goods (ARTG) information for VAFSEO vadadustat 150 mg tablet blister pack.
- VAFSEO vadadustat 450 mg tablet blister pack (384152)ARTGAustralian Register of Therapeutic Goods (ARTG) information for VAFSEO vadadustat 450 mg tablet blister pack.
- VAFSEO vadadustat 300 mg tablet blister pack (384154)ARTGAustralian Register of Therapeutic Goods (ARTG) information for VAFSEO vadadustat 300 mg tablet blister pack.
- VAFSEO (Adjutor Healthcare Pty Ltd)Prescription medicine registrationActive ingredients: vadadustat.
- AusPAR: TruseltiqAustralian Public Assessment Report (AusPAR)AusPAR for Truseltiq (infigratinib) for treatment of adults with metastatic cholangiocarcinoma with FGFR2 fusion or other rearrangement.
- AusPAR: KimmtrakAustralian Public Assessment Report (AusPAR)For the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
- Notice for sabizabulin (Adjutor Healthcare Pty Ltd)Designation or determinationProvisional determination
- KIMMTRAK (Adjutor Healthcare Pty Ltd)Prescription medicine registrationActive ingredients: tebentafusp.
- KimmtrakPrescription medicine decision summaryTGA decision: KIMMTRAK (tebentafusp) is approved to treat unresectable or metastatic uveal melanoma in HLA-A*02:01 positive patient.